RRM2 and cancer: For example, in cancer cells with loss of SETD2, a decrease in levels of the RRM2 ribonucleotide reductase subunit can create a vulnerability, which can be exploited by the WEE1 inhibitor adavosertib that further reduce RRM2 levels, leading to S phase arrest as a result of a depleted dNTP pool (Pfister et al., 2015).